LIPID METABOLISM INDICATORS IN PATIENTS WITH STAGE II ESSENTIAL HYPERTENSION DEPENDING ON THE PRESENCE OF CONCOMITANT METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

Authors:

Abstract:

170 patients with stage II hypertension were examined. Based on the presence of metabolic dysfunction-associated steatotic liver disease (confirmed by ultrasound and FibroTest), all examined patients were divided into two clinical groups. The first clinical group included 109 patients with stage II hypertension and steatotic liver disease, and the second group included 61 patients with stage II hypertension without liver damage. The control group included 30 practically healthy individuals. In addition to general clinical and laboratory examinations, all patients underwent determination of serum lipid profile indicators and lipoprotein (a). Comorbidity of stage II hypertension and metabolic dysfunction-associated steatotic liver disease was accompanied by a significant (p<0.05) increase in the concentration of total cholesterol, LDL-cholesterol, VLDL cholesterol, triglycerides, atherogenicity index, and lipoprotein (a) both in comparison with healthy individuals and patients with stage II hypertension without concomitant liver damage, which may indicate a significantly increased risk of developing atherosclerosis and other cardiovascular diseases in these patients.

Keywords:

arterial hypertension hypertensive disease metabolic dysfunction-associated steatotic liver disease lipoprotein (a) lipid spectrum

References:

1. Badmus OO, Hinds TD Jr, Stec DE. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease. Curr Hypertens Rep. 2023 Aug;25(8):151-162. doi: 10.1007/s11906-023-01242-8.
2. Cui D, Yu X, Guan Q, Shen Y, Liao J, Liu Y, et al. Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets. Mol Biomed. 2025 Oct 9;6(1):72. doi: 10.1186/s43556-025-00321-3.
3. Dongier A, Delwaide J, Louis É, Loly JP. Nouvelles recommandations concernant les maladies stéatosiques du foie : ce qu’il faut en retenir [Updated recommendations on metabolic dysfunction-associated steatotic liver disease]. Rev Med Liege. 2025 May;80(5-6):401-409. PMID: 40518897. [in French].
4. ESC/ESH 2018 Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): 3021-3104. DOI:10.1093/eurheart/ehy339.
5. ESC 2024 Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024. DOI:10.1093/eurheartj/ehae178.
6. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031.
7. Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. ESC/EAS Scientific Document Group et al. Atherosclerosis. 2025; Volume 409, 120479.
8. Gofton C, George J. Updates in fatty liver disease: Pathophysiology, diagnosis and management. Aust J Gen Pract. 2021 Oct;50(10):702-707. doi: 10.31128/AJGP-05-21-5974.
9. Gribenyuk OV, Kuzminova NV, Osovska NY, Knyazkova II. Arterial hypertension, obesity and non-alcoholic fatty liver disease: is there any connection. Arterial Hypertens, 2016; 20 (4), 216-227. doi:10.5603/AH.2016.0025.
10. Muñoz Rossi FA, Salazar Agudelo J, Quinapanta Castro NI, Mosquera SZ, Mejia Fajardo MC, Mosquera López ED, et al. Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers. Cureus. 2024 Jun 24;16(6):e63019. doi: 10.7759/cureus.63019.
11. Nam JS, Park K, Baik SJ, Park JS. Lipoprotein(a) level predicts the development of nonalcoholic fatty liver disease in Korean adults: A retrospective longitudinal study. Medicine (Baltimore). 2024 May 31;103(22):e38411. doi: 10.1097/MD.0000000000038411.
12. Nikoli A, Orfanidou M, Goulas A, Goulis DG, Polyzos SA. Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2024 Dec;39(12):2572-2581. doi: 10.1111/jgh.16768.
13. Wu T, Ye J, Shao C, Lin Y, Wang W, Feng S, et al. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease. Front Med (Lausanne). 2023 Aug 24;10:1229064. doi: 10.3389/fmed.2023.1229064.

Publication:

«World of Medicine and Biology» Vol. 22 No. 1 (2026) , с. 93-97
УДК 616.12-008:616.36-003.826

DOI:

https://doi.org/10.26724/2079-8334-2026-1-95-93-97